PLK1 and melanoma: While treatment with the PLK1 inhibitor volasertib has been shown to cause cell-cycle arrest, decreased cell viability and increased apoptosis in melanoma cells [67,75], we have found that this is also true for melanoma cells that are resistant to vemurafenib.